Treosulfan clinical trials
Also written Ovastat, Trecondi and Grafapex.
How each study uses treosulfan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the treosulfan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 21 Jan 2025 · GRAFAPEX · NDA 214759 (FDA, Drugs@FDA)
- European Union
- 20 Jun 2019 · Trecondi · EMEA/H/C/004751 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
40 studies that test it; most in 2009 (5)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 3 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 5 |
| 2010 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 32
medac GmbH (7) · Fred Hutchinson Cancer Center (7) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (4) · St. Anna Kinderkrebsforschung (3) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1) · Ciceri Fabio (1) · University Hospital Muenster (1) · Novartis Pharmaceuticals (1)
Often tested with
Tested in the same studies.
Fludarabine (10) · Thiotepa (4) · Etoposide (3) · Busulfan (2) · Fludarabine phosphate (2) · Pioglitazone (2) · Antilymphocyte Serum (2) · Muromonab-CD3 (2)
Related medicines
As reviewed, each with the page that says it.
- One of Alkylating agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test treosulfan.
- Jan 2027Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage SyndromePhase 2 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Apr 2027Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological MalignanciesPhase 2 · Fred Hutchinson Cancer Center
Studies
Open first, then newest update. How each study uses treosulfan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 40
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant DisordersRecruitingPhase 2Fred Hutchinson Cancer CenterNCT03980769Written as TreosulfanHow we know
- Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic LeukaemiaRecruitingPhase 2/3St. Anna KinderkrebsforschungNCT01949129Written as TreosulfanHow we know
- Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic TransplantationRecruitingPhase 2Technische Universität DresdenNCT07025824Written as Treosulfan (Treo)How we know
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological MalignanciesRecruitingPhase 2Fred Hutchinson Cancer CenterNCT04195633Written as TreosulfanHow we know
- FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AMLNot yet recruitingPhase 2Institut Paoli-CalmettesNCT07598110Written as fludarabine and treosulfanHow we know
- MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological DiseasesRecruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT07493538Written as TreosulfanHow we know
- Study of Treosulfan-Based Conditioning for HSCT in Nijmegen Breakage SyndromeNot yet recruitingPhase 2Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyNCT07316595Written as Treosulfan (Treo)How we know
- Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with HemoblastosisRecruitingPhase 2/3Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyNCT06756152Written as Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150How we know
- Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma PatientsRecruitingPhase 2Insel Gruppe AG, University Hospital BernNCT05636787Written as TreosulfanHow we know
- Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage SyndromeRecruitingPhase 2Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyNCT06198842Written as TreosulfanHow we know
- Dose-range Finding Treosulfan-based ConditioningCompletedPhase 1/2medac GmbHNCT01063647Written as TreosulfanHow we know
- Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid LeukemiaTerminatedPhase 2Fred Hutchinson Cancer CenterNCT04994808Written as TreosulfanHow we know
- Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan PharmacokineticsCompletedPhase 1medac GmbHNCT05534620Written as TreosulfanHow we know
- Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)CompletedPhase 2Fred Hutchinson Cancer CenterNCT04965597Written as TreosulfanHow we know
- Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant DiseasesCompletedPhase 2medac GmbHNCT02349906Written as TreosulfanHow we know
- Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid LeukemiaActive, not recruitingPhase 2Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaNCT07232953Written as Fludarabine + TreosulfanHow we know
- Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic TransplantCompletedPhase 2Ciceri FabioNCT03961919Written as TreosulfanHow we know
- Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood TransplantCompletedPhase 2Fred Hutchinson Cancer CenterNCT00796068Written as TreosulfanHow we know
- Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic LeukemiaCompletedPhase 2Fred Hutchinson Cancer CenterNCT00860574Written as treosulfanHow we know
- Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaStatus unknownPhase 2Fred Hutchinson Cancer CenterNCT01894477Written as TreosulfanHow we know
See all 40 studies that test treosulfan →
Given beside what is tested · 2 — treosulfan is usual care or a partner of the new treatment
- Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited DisordersCompletedPhase 2Fred Hutchinson Cancer CenterNCT00919503Written as TreosulfanHow we know
- T&B Depletion Non MalignantStatus unknownPhase 2Franco LocatelliNCT01810926Written as TreosulfanHow we know
Codes
What other systems call treosulfan · ClinicalTrials.gg INT002696
- MeSH (NLM) C018404treosulfanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) CO61ER3EPITREOSULFANConfirmed FDA, NLM, Wikidata
- RxNorm 38508Confirmed FDA, Wikidata
- Wikidata Q7838652treosulfanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1257TreosulfanOne source FDA
- DrugBank DB11678One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C018404 | treosulfan | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | CO61ER3EPI | TREOSULFAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 38508 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7838652 | treosulfan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1257 | Treosulfan | One source FDA |
| DrugBank | DB11678 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.